Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

I Shapiro

Showing results (951-960 of 1,171) with videos related to

Pageof 118
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
Scientific Reports|October 5, 2016
Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic CardiomyopathyJiang Liu, Jiang Tian, Muhammad Chaudhry, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Diagnostic Microbiology and Infectious Disease|June 8, 2024
A standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsisNatalie N Whitfield, Catherine A Hogan, James Chenoweth, et al.
Cancer Research|October 11, 2023
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT CarcinomaR Taylor Durall, Julianna Huang, Luke Wojenski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Scientific Reports|October 21, 2017
Corrigendum: Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic CardiomyopathyJiang Liu, Jiang Tian, Muhammad Chaudhry, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Pageof 118

Showing results (951-960 of 1,171) with videos related to

Sort By:
Pageof 118
Proceedings of the National Academy of Sciences of the United States of America|October 3, 2013
Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistanceNeil Johnson, Shawn F Johnson, Wei Yao, et al.
Future Oncology (London, England)|January 18, 2022
CSF1 receptor inhibition of tenosynovial giant cell tumor using novel disease-specific MRI measures of tumor burdenCharles Peterfy, Yan Chen, Peter Countryman, et al.
Scientific Reports|October 5, 2016
Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic CardiomyopathyJiang Liu, Jiang Tian, Muhammad Chaudhry, et al.
Cancers|September 9, 2022
BMS-986158, a Small Molecule Inhibitor of the Bromodomain and Extraterminal Domain Proteins, in Patients with Selected Advanced Solid Tumors: Results from a Phase 1/2a TrialJohn Hilton, Mihaela Cristea, Sophie Postel-Vinay, et al.
Diagnostic Microbiology and Infectious Disease|June 8, 2024
A standardized protocol using clinical adjudication to define true infection status in patients presenting to the emergency department with suspected infections and/or sepsisNatalie N Whitfield, Catherine A Hogan, James Chenoweth, et al.
Cancer Research|October 11, 2023
The BRD4-NUT Fusion Alone Drives Malignant Transformation of NUT CarcinomaR Taylor Durall, Julianna Huang, Luke Wojenski, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 26, 2009
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumorsKwok-K Wong, Paula M Fracasso, Ronald M Bukowski, et al.
Scientific Reports|October 21, 2017
Corrigendum: Attenuation of Na/K-ATPase Mediated Oxidant Amplification with pNaKtide Ameliorates Experimental Uremic CardiomyopathyJiang Liu, Jiang Tian, Muhammad Chaudhry, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2021
Phase II Clinical Trial of Everolimus in a Pan-Cancer Cohort of Patients with mTOR Pathway AlterationsElio Adib, Katarzyna Klonowska, Krinio Giannikou, et al.
Pageof 118